Scientific Advisory Board

SDS Optic Inc. Scientific Advisory Board is strictly related to the company’s technologies development. Members of this exclusive circle are distinguished scientists, physicians and other qualified individuals. Main goal of the Board is to advise the Company with respect to its technology, strategy and development as well as scientific related business activities.

Development of the disruptive novel medical technologies is a complex process that involves scientific, organizational, regulatory and business challenges. Apart from the day to day work of our specialists, clinical and industrial partners, we get support and advice from prominent scientists, clinicians and entrepreneurs.

SDS Optic Inc. SAB goals

Support SDS Optic’s mission and strategic goals

Advising on the technology development

Attending the SAB meetings

Providing advice and recommendations
about biotech projects

Advocating for SDS Optic Inc.
with the global med-tech or pharma market

Building the network of contacts with
clinics, hospitals and laboratories 

Commenting, advising and evaluating
the SDS Optic’s strategy performance

Providing feedback to the management board

Scientific Advisory Board Members

Magdalena Staniszewska
PhD, DSc

MORE Over 20 years of experience in R&D projects, managing high-specialized laboratories, and successful cooperation between the academic community and biotechnology industry gained in the world’s best scientific centers – Harvard Medical School, Boston, MA and CWRU, Cleveland, OH in the USA. Experienced public speaker, and co-author of a number of patents implemented, among others, by Novartis AG and numerous scientific publications… CHECK FULL PROFILE

Prof. Wojciech Polkowski
MD, PhD, DSc

MORE Surgical oncologist, graduated from the Medical University of Lublin. He completed post-graduate studies at the European School of Gastroenterological Surgery of the Academic Medical Center of the University of Amsterdam, where he obtained a doctorate degree. He has served for 15 years as the head of the Clinic of Surgical Oncology at the Medical University in Lublin… CHECK FULL PROFILE
Avi Dukler - SAB Member

Avi Dukler

MORE During his 23+ years in the diagnostics industry, Dr. Dukler co-founded Kepler Diagnostics, Inc, Fantestico Inc, and Glycominds Ltd., where he commercialized innovative digital health and clinical diagnostics products. Inventor and author of multiple patents and scientific publications, completed several transactions including M&A, asset sales, IP licenses, private and public fundraising… CHECK FULL PROFILE

Prof. Andrius Kazlauskas

MORE Dr. Kazlauskas obtained first-hand experience and insight into translational research while working in the Ophthalmology Department of F. Hoffman-La Roche in Basel, Switzerland (SMI: RO). He returned to academia to investigate the pathogenesis of diabetic retinopathy. Currently serves as Professor at University of Illinois Chicago… CHECK FULL PROFILE

Arun Balakumaran

MORE Oncologist, Scientist, and Biotechnology Executive. He is an MD, Ph.D., Board Certified in Hematology and Medical Oncology with a Master’s degree in Health Care Management at Harvard University. He built his experience in global companies such as Amgen, Allogene and Merck… CHECK FULL PROFILE

Our vision

Increasing the survival rate of cancer patients by 30% by 2030

SDS Optic S.A. creates and develops diagnostic and monitoring solutions, combining optoelectronics (photonics) with molecular biology, medical bioengineering and immunochemistry.

The mission of SDS Optic S.A. is one of the main objectives that many countries and international organizations have committed themselves to achieving. On 4 February 2017, on World Cancer Day, the World Health Organization published a new list of recommended medical procedures and services, that are required at an early stage of cancer development, to increase the chances of curing the patients.

According to the WHO, it is necessary to intensify the global development of diagnostic solutions that can be applied at the very beginning of the diagnostic pathway for people with suspected cancer.

Many countries have committed themselves to the Sustainable Development Goals (SDGs). One of the points of this agenda is to reduce premature deaths caused by cancer by 1/3 by 2030.

Our mission and objective
is to increase the survival
of cancer patients
by 30% by 2030.

Urządzenie inPROBE - wizja SDS Optic S.A.

WHO is not the only international institution that, like SDS Optic, wishes to fight for the life of cancer patients. The objective of improving the quality of life and extending the life expectancy of 3 million people by 2030 through prevention and treatment, and supporting cancer patients and their families, was also included in the European Commission’s Horizon Europe document.

SDS Optic S.A. consciously the mission of increasing cancer survival by 30% by 2030 in its DNA. Research, reports and the direction of development of global and renowned organizations indicate that effective solutions for the diagnosis of diseases at the earliest possible stage can save human life and health.

That’s why we created inPROBE – a micron optical biosensor for the detection of bioelements in real time, in vivo (inside the human body). You can find more on how our technology works at

Who we are

SDS Optic S.A. combines
Photonics, Molecular Biology, Chemistry and Medical Bioengineering
in one unique technological platform called inPROBE®

SDS Optic S.A. effectively combines the fields of molecular biology, photonics, immunochemistry and biomedical engineering. We are a team of scientists and specialists who has set themselves the objective of supporting medicine and improving the quality of life of people around the world. We implement it by creating innovative technologies that save human life and health.

Zespół SDS Optic SA - kim jesteśmy

The flagship SDS Optic project is the world unique inPROBE® optical fibre micro-probe, which enables real-time diagnosis of breast cancer.

Urządzenie inPROBE

Our story

Founders of SDS Optic and inventors of the inPROBE® technology Magdalena and Marcin Staniszewski are Polish scientists, who gained experience years of practice in the United States, working with institutions such as NASA or Harvard Medical School. It was overseas that the idea of developing diagnostic technology was born, combining optoelectronics with molecular biology. The pair of scientists decided to return to their homeland in order to set up their biotechnology start-up there. The company was officially established in 2013 in Lublin (Poland). At the end of 2016, a 6 micron fibre probe was developed – the cornerstone of the inPROBE® technology, and preclinical trials were carried out on human cells in vitro in the area of detection of HER2 biomarker positive breast cancer.

The first successes resulted in patent applications. By 2020, the Company has achieved further project development milestones. We created a modern laboratory infrastructure and performed pre-clinical trials on animals. The promising results of the research confirmed the legitimacy of developing this new, breakthrough diagnostic technology.

2021 and the outbreak of the coronavirus pandemic changed the reality of many companies. Clinics and hospitals have focused on the fight against the virus, and this situation has prevented planned clinical trials on human subjects. We used this time to reliably prepare for research, for certification and global commercialization of our technology. We have opened a new 700m2 laboratory space and started work on the application of microprobe in the area of detection of infectious diseases (including SARS-CoV-2).

2022 was marked with numerous important events. We made our debut on the NewConnect stock exchange and began clinical trials of our device. We regularly increase the set of competences of our teams and employ outstanding specialists in the fields of science, technology and business development. This year, we have also launched a Clean Room for the manufacture of the optoelectronic part of inPROBE® biosensors.

inPROBE logo
Historia firmy SDS Optic SA

Our Mission and Vision

Currently, the key stage of cancer diagnosis is biopsy and histopathological examination, which are to answer the question, among others, whether there are tumor markers in the tissues collected from the patient. Today, the gold standard in histopathology is the staining of immunohistochemical hormonal receptors. To simply the entire for illustrative purposes the colour represents the test result. Depending on the intensity of tissue staining, histologists determine whether the patient has cancer and at what stage of development it is. The test result is therefore not a numerical value, but only a relative visual assessment..

The technology that we invented at SDS Optic S.A. will allow to indicate, and that in real time, the exact mathematical result related to the concentration of the tested molecule.

The vision of SDS Optic is to increase the survival rate of cancer patients by approx. 30% by 2030 – these are hundreds of thousands of women around the world who, thanks to our technology, can be quickly diagnosed, and will have a chance to be cured – dr. hab. Magdalena Staniszewska, the originator of the microprobe, has been associated with the Harvard Medical School in Boston for many years.

SDS Optic gathers the most talented scientists in the field of molecular biology, chemistry and biotechnology. Our team is constantly developing, also in the business sphere, currently managed by our Operations and Business Development Director Mateusz Sagan, achieving further successes and presenting itself both at global events and in the media.

The development of innovative technology for the manufacture of laser microprobes is possible thanks to significant public support that SDS Optic was able to secure. The Polish National Centre for Research and Development co-financed the project under the STRATEGMED and PatentPlus programmes. In addition, INNOventure – a fund of the Kraków Technology Park and private investors created as part of the NCBiR – BRIdge Alfa initiative – also invested PLN 3 million in the development of SDS Optic.

SDS Optic S.A. is one of the largest beneficiaries of the EASME agency under Horizon 2020 framework programme of the European Commission. The company belongs to the Lublin Medicine – Medical & Wellness Cluster and to the Polish Technological Platform on Photonics.